Pharmacokinetics
Research Library
|
|
BIOCIUS Life Sciences (formerly BioTrove RapidFire)
|
Cytochrome P450s (CYP450) mediate the biotransformation of drug compounds. Metabolism of multiple test compounds by the same CYP450 isoform can alter reaction kinetics and result in adverse drug-drug interactions (DDI). Therefore, high throughput-DDI assays are valuable tools in the go/no-go decision-making process in drug discovery. Mass spectrometry-based CYP450 assays have emerged as the ...
|
|
|
GVK Biosciences Private Limited
|
Recent industry analyst reports predict that worldwide pharmaceutical industry revenues will grow at a compound annual growth rate (CAGR) of 8.58% through 2008. Worldwide biotechnology revenues are expected to grow at a compound annual growth rate of 25.96% through 2008 – this large growth rate is not surprising as many biotechnology and biopharmaceutical companies are just now moving products ...
|
|
|
GVK Biosciences Private Limited
|
This paper explores the opportunities to improve the R&D process. It proposes new technologies will enable the adoption of virtual R&D; and by operating in a more connected world, the industry in collaboration with researchers, governments, healthcare payers and providers, can address the changing needs of society more effectively.
|
|
|
The Jackson Laboratory
|
Epidemiologic analysis has revealed the association of psoriasis with inflammatory bowel disease (IBD) in humans. In mice, transfer of CD45RBhi CD4+ naive T cells into immunodeficient animals induces colitis and psoriasis-like phenotypes. This sample study describes the utility of such an adoptive transfer model to evaluate novel compounds for the treatment of IBD and psoriasis.
|
|
|
SGS Life Science Services - Clinical Research
|
Over the past number of years HIV medication development mainly focused on treatment simplification with the development of fixed dose combination tablets. However, during the last two years, significant progress was made to increase the number of new compounds available to patients; not only did the FDA approve a new protease inhibitor (duranavir, 2006) and a NNRTI (Etravirine, 2008), there was ...
|
|
|
|
